Immunomedics

Jun 13, 07
	NEW STORY
11:00 ET	Immunomedics Set to Join Russell 3000 Index
Jun 11, 07
08:00 ET	Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study
Jun 05, 07
11:46 ET	Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
Jun 04, 07
15:00 ET	Immunomedics Reports New and Updated Clinical Results from Dose De-Escalation Study with hA20 in Lymphoma Patients
09:00 ET	Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
08:00 ET	Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
May 30, 07
08:00 ET	Immunomedics to Present at the Society of Nuclear Medicine 54th Annual Meeting
May 29, 07
08:00 ET	Immunomedics To Present at 43rd Annual Meeting of the American Society of Clinical Oncology
May 10, 07
08:00 ET	Immunomedics to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
May 08, 07
16:30 ET	Immunomedics Announces Third Quarter Fiscal 2007 Results
May 07, 07
16:30 ET	Immunomedics Completes $24 Million Registered Direct Offering of Common Stock
May 02, 07
08:30 ET	Immunomedics to Raise Gross Proceeds of $24 Million in Registered Direct Offering of Common Stock
Apr 17, 07
16:00 ET	Immunomedics Develops Novel Immunotoxin for Therapy of Prostate and Lung Cancers
14:40 ET	Early Stage Pancreatic Cancer Expresses Antigen Targeted by Immunomedics' PAM4 Antibody
Feb 08, 07
20:00 ET	Immunomedics Announces Second Quarter Fiscal 2007 Results
Jan 10, 07
16:30 ET	Immunomedics Mourns the Loss of Board Member Richard Pivirotto
Dec 11, 06
08:00 ET	Low Doses of Humanized Anti-Cd20 Antibody Reported Active in Non-Hodgkin's Lymphoma
Dec 10, 06
09:00 ET	Novel Protein Constructs Active Against Lymphoma In Animal Models
Dec 07, 06
11:30 ET	Immunomedics to Be Awarded U.S. Patent for the Treatment of B-Cell Lymphomas, Leukemias and Autoimmune Diseases
Dec 06, 06
12:00 ET	Immunomedics Announces Outcome of 2006 Annual Meeting of Shareholders
Dec 04, 06
15:00 ET	Immunomedics to Present at American Society of Hematology 48th Annual Meeting
08:30 ET	Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Nov 21, 06
14:00 ET	Immunomedics to Present at Lazard Capital Markets Third Annual Life Sciences Conference
Nov 14, 06
14:00 ET	FDA Allows Resumption of Lupus Trials with Epratuzumab
Nov 13, 06
08:30 ET	Epratuzumab and Rituximab Have Different Modes of Action
Nov 06, 06
16:00 ET	Immunomedics Announces First Quarter Fiscal 2007 Results
Oct 25, 06
14:59 ET	Immunomedics to Present at Upcoming Conferences
Aug 25, 06
16:00 ET	Immunomedics Announces Fiscal 2006 Results
Jun 05, 06
14:00 ET	Humanized anti-CD20 Antibody Appears Safe and Active in Non-Hodgkin's Lymphoma in Phase I/II Study
08:00 ET	Immunomedics Constructs New Bispecific Antibodies Using the Dock and Lock (DNL) Technology
Jun 02, 06
08:00 ET	Repeated Radioimmunotherapy With 131I-Labetuzumab in Colorectal Cancer With Liver Metastases Found Safe and Well-Tolerated in Initial Phase II Study
Jun 01, 06
16:30 ET	Immunomedics to Present at 53rd Annual Meeting of the Society of Nuclear Medicine
May 11, 06
08:00 ET	Immunomedics to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference
May 10, 06
16:00 ET	Immunomedics Announces Third Quarter Fiscal 2006 Results
02:00 ET	Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Apr 25, 06
08:00 ET	Immunomedics and IBC Pharmaceuticals Report on a Novel Protein Engineering Platform Technology
Apr 24, 06
13:39 ET	Epratuzumab for Immunotherapy of Lupus Results Published
Feb 14, 06
17:00 ET	Immunomedics Announces Second Quarter Fiscal 2006 Results
Dec 16, 05
14:19 ET	New Diagnostic Assay for Pancreatic Cancer Reported in Journal of Clinical Oncology
Dec 15, 05
08:30 ET	Immunomedics Reports Preclinical Results on New Therapeutic
Dec 12, 05
08:30 ET	Immunomedics Reports Humanized Anti-CD20 Antibody Appears Safe and Active in Non-Hodgkin's Lymphoma
Dec 09, 05
08:30 ET	Immunomedics Reports Updated Clinical Results of Epratuzmab-Rituximab Combination in Lymphoma
Dec 07, 05
11:00 ET	Immunomedics Announces Outcome of 2005 Annual Meeting of Shareholders
Nov 28, 05
08:30 ET	Immunomedics Describes Alleviate Trials Design
Nov 15, 05
08:32 ET	Immunomedics Reports Updated Clinical Results for Epratuzumab in Sjogren's Syndrome at the 2005 ACR/ARHP Annual Scientific Meeting
Nov 07, 05
16:30 ET	Immunomedics Announces First Quarter Fiscal 2006 Results
Nov 03, 05
08:30 ET	Immunomedics to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
Oct 18, 05
08:35 ET	Immunomedics Resale Shelf Registration Statement Declared Effective
Sep 21, 05
12:04 ET	Phase-II Trial Shows Improved Survival of Colorectal Cancer Patients Receiving Radioimmunotherapy Post Salvage Resection of Liver Metastases
Sep 19, 05
16:30 ET	Immunomedics Files Resale Shelf Registration Statement on Behalf of Certain Security Holders
Sep 08, 05
16:30 ET	Immunomedics Announces Fiscal 2005 Results
Sep 06, 05
08:33 ET	Immunomedics Announces Positive Ruling From Nasdaq Appeal Panel
Sep 02, 05
14:00 ET	Immunomedics Announces Change in Senior Management
Aug 19, 05
11:55 ET	Immunomedics Announces Approval of Two Proposals at Special Meeting of Stockholders
Jul 05, 05
19:49 ET	Immunomedics Commences Exchange Offer For 5% Senior Convertible Notes And Common Stock Warrants
Jun 20, 05
08:30 ET	David M. Goldenberg Receives Highest Award from Society of Nuclear Medicine
Jun 16, 05
08:30 ET	Immunomedics Awarded U.S. and Australian Patents for Autoimmune Disease Therapy with CD22 Antibodies
Jun 14, 05
18:23 ET	Immunomedics to Appeal Nasdaq Ruling and Files Preliminary Proxy Material for Stockholder Meeting
Jun 10, 05
08:30 ET	Immunomedics Reports Initial Clinical Results for Epratuzumab in Sjogren's Syndrome
Jun 08, 05
18:52 ET	David M. Goldenberg Provides Intra-Family Stock Transfer Details
Jun 01, 05
14:21 ET	Immunomedics Initiates Two Pivotal Phase III Trials in Lupus
May 26, 05
08:12 ET	Immunomedics Announces Conference Call and Webcast
May 25, 05
19:12 ET	Immunomedics Will Host a Conference Call and Webcast on Thursday, May 26, at 9 A.M. ET
May 12, 05
10:46 ET	Immunomedics to Present at the American Society of Clinical Oncology Annual Meeting
May 05, 05
16:31 ET	Immunomedics Announces Third Quarter Fiscal 2005 Results
May 02, 05
08:32 ET	Immunomedics Completes $37 Million Financing
Apr 28, 05
16:31 ET	Immunomedics to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
Apr 27, 05
13:56 ET	Immunomedics Announces $36 Million Senior Convertible Notes and Warrant Offering
Mar 28, 05
11:21 ET	Immunomedics' Humanized anti-CD20 Antibody Effective in Severe Lupus
Feb 04, 05
16:30 ET	Immunomedics Announces Second Quarter Fiscal 2005 Results
Jan 19, 05
10:04 ET	Immunomedics Announces Canadian Approval of LeukoScan(R)
Jan 11, 05
14:29 ET	Immunomedics Elects Don C. Stark to Board of Directors
Jan 05, 05
10:51 ET	Immunomedics' Epratuzumab On FDA Fast Track for Lupus Therapy
Dec 01, 04
11:00 ET	Immunomedics Reviews Clinical Advances at 2004 Annual Meeting of Shareholders
Nov 03, 04
16:57 ET	Immunomedics Announces First Quarter Fiscal 2005 Results
Oct 20, 04
12:06 ET	Immunomedics Announces Plan to Conduct Registration Trials in Lupus
08:01 ET	Immunomedics To Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
Oct 19, 04
15:30 ET	Immunomedics Reports Updated Clinical Results on Lupus at the ACR/ARHP 68th Annual Scientific Meeting
Oct 12, 04
08:00 ET	Immunomedics Names Brian A. Markison to Board of Directors
Sep 30, 04
10:05 ET	Immunomedics Reports Research and Preclinical Advances at the 16th EORTC/AACR/NCI Conference
Sep 29, 04
12:31 ET	Patent Infringement Suit Settled
Sep 08, 04
17:30 ET	Immunomedics Announces Fiscal 2004 Results
09:01 ET	Immunomedics To Present at Bear Stearns 17th Annual Healthcare Conference
Aug 02, 04
09:02 ET	Immunomedics, Inc. Raises $15 Million in Sale of Common Stock
Jul 07, 04
09:48 ET	CIS bio international Enters Into a Settlement With Immunomedics Regarding CEA Antibody Technology
Jun 23, 04
17:36 ET	Appeals Court Rules in Immunomedics' Favor; Remands Case to Lower Court for Further Consideration of Infringement by Cytogen Under the Doctrine of Equivalents
Jun 21, 04
12:31 ET	Immunomedics Reports on Radioimmunotherapy at 51st Annual Meeting of the Society of Nuclear Medicine
Jun 07, 04
08:07 ET	Immunomedics Reports Advances in Lymphoma and Multiple Myeloma Therapy at the 40th Meeting of American Society of Clinical Oncology
Jun 03, 04
13:46 ET	New Data on Immunomedics' Cancer Therapeutics to Be Presented at 40th Annual Meeting of American Society of Clinical Oncology (ASCO)
May 11, 04
18:25 ET	Immunomedics Announces Third Quarter Fiscal 2004 Results
14:30 ET	Immunomedics Reports First Clinical Results with Epratuzumab in Systemic Lupus Erythematosus (SLE)
Mar 29, 04
10:21 ET	Immunomedics and IBC Pharmaceuticals Develop Novel Trivalent Fusion Protein for Radioimmunotherapy
Feb 25, 04
08:04 ET	Immunomedics to Present at the 7th Annual Lehman Brothers Global Healthcare Conference
Feb 09, 04
17:07 ET	Immunomedics Announces Second Quarter Fiscal 2004 Results
Jan 26, 04
08:08 ET	Immunomedics Reports Phase II Colorectal Cancer Therapy Data at GI Cancer Symposium
Jan 15, 04
08:00 ET	Immunomedics Awarded U.S. Patent for Humanized CEA Antibody Conjugates
Jan 13, 04
11:38 ET	Immunomedics to Receive $10 Million Financing
Jan 07, 04
09:34 ET	Immunomedics to Present at the 22nd Annual JP Morgan Healthcare Conference
Dec 29, 03
08:01 ET	Immunomedics Publishes Successful Results With New Cancer Therapeutic
Dec 22, 03
08:04 ET	Dutch Supreme Court Sustains Immunomedics Patent
Dec 08, 03
10:00 ET	Multiple Presentations on Immunomedics' Humanized CD22 and CD74 Antibodies Given at American Society Of Hematology (ASH) Meeting
Dec 05, 03
08:12 ET	Study Shows That Humanized Antibody Conjugated With Radioiodine by a New, Proprietary, Method Improves Therapeutic Effectiveness in Human Breast Cancer Model
Dec 03, 03
11:00 ET	Immunomedics Highlights Advances In Its Therapeutic Pipeline At 2003 Annual Meeting of Shareholders
Nov 20, 03
15:55 ET	Immunomedics' Bispecific Antibody Technology Shows Three-Fold Increase In Radiation Dose Delivered To Colon Cancer Model
09:39 ET	Immunomedics Reports on New Drug Candidate at Cancer Conference
Nov 13, 03
17:35 ET	Immunomedics Announces First Quarter Fiscal 2004 Results
Nov 11, 03
09:08 ET	Immunomedics in Discussions to Regain Development Rights From Amgen for Epratuzumab
Nov 07, 03
13:44 ET	Immunomedics Announces Publication of Abstracts Involving Four Product Candidates on American Society of Hematology (ASH) Website
Oct 23, 03
14:49 ET	Immunomedics' Subsidiary, IBC Pharmaceuticals, Inc., Enters Research Collaboration With Schering AG
Oct 20, 03
14:38 ET	Immunomedics to Present at the 5th Annual Rodman & Renshaw Techvest Healthcare Conference
Sep 22, 03
08:08 ET	Immunomedics to Present at UBS Global Life Sciences Conference
Sep 05, 03
14:27 ET	Immunomedics to Present at the Bear Stearns 16th Annual Healthcare Conference
Aug 21, 03
12:37 ET	Immunomedics Reports Continued Progress on Product Development
Aug 13, 03
17:36 ET	Immunomedics Announces Fiscal 2003 Results
Jun 25, 03
07:30 ET	Immunomedics Reports Results With Proprietary Diagnostic Imaging Product
Jun 24, 03
07:30 ET	Immunomedics Reports on Advances in Cancer Imaging Products
Jun 23, 03
07:30 ET	Immunomedics Reports Progress in Cancer Therapy At 50th Annual Meeting of the Society of Nuclear Medicine
Jun 01, 03
19:00 ET	Immunomedics Reports on Two Novel Antibodies for B-Cell Tumor Therapy
14:24 ET	Anti-CEA Monoclonal Antibody Combined With Chemotherapy Demonstrates Positive Preclinical Results in Colon and Breast Cancers
May 28, 03
12:57 ET	Immunomedics Completes NJEDA Bond Financing for Large-Scale Manufacturing Facility
May 12, 03
16:08 ET	Immunomedics to Appeal Patent Infringement Decision
May 08, 03
08:31 ET	Immunomedics Reports Fiscal Third Quarter 2003 Results
May 06, 03
08:05 ET	Immunomedics Awarded U.S. Patent For Improved Method Of Labeling Antibodies With Iodine-131
Apr 21, 03
12:10 ET	IBC Pharmaceuticals Elects Two Distinguished Scientists to Board of Directors
Apr 15, 03
08:04 ET	Immunomedics Granted Additional Patent for Proprietary Treatment of Infectious Disease
Apr 09, 03
08:28 ET	CIS Bio International Enters Into a Settlement With Immunomedics Regarding CEA Antibody Technology
Feb 10, 03
17:52 ET	Immunomedics Reports Fiscal Second Quarter 2003 Results
Jan 15, 03
09:22 ET	Immunomedics' Scientists Report on Improved Linker for Yttrium Isotope Used With Epratuzumab in Lymphoma Therapy
Jan 03, 03
08:00 ET	Immunomedics, Inc. to Present at 21st Annual J.P. Morgan H&Q Healthcare Conference
Dec 09, 02
09:04 ET	Results of Epratuzumab for Non-Hodgkin's Lymphoma Therapy Presented At American Society Of Hematology Meeting
08:24 ET	Immunomedics Reports on New Humanized Antibody Therapeutics at American Society of Hematology Meeting
Dec 04, 02
10:45 ET	Immunomedics Reviews Progress at Annual Meeting of Shareholders
Nov 11, 02
16:15 ET	Immunomedics Reports Fiscal First Quarter 2003 Results